## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1642

Hohneker, John Arthur et al.

Examiner: Fetterolf, Brandon J

INTERNATIONAL APPLICATION NO: PCT/EP03/05988

FILED: June 06, 2003

U.S. APPLICATION NO: 10/517074 35 USC §371 DATE: April 19, 2005

FOR: Combinations Comprising Epothilones and Pharmaceutical Uses

Thereof

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

supplemental to the Information Disclosure Statement filed September 1, 2005.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

- This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c) or 37 C.F.R. §1.97(d).
- A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report and copies are enclosed herewith except for the US patents/applications.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation One Health Plaza, Bldg. 101 East Hanover, NJ 07936 (862) 778-7824

Date: 6/3/10

Respectfully submitted

George Dohmann Attorney for Applicant Reg. No. 33,593